GSK240927C52000
- 0.05
- 0.000.00%
GlaxoSmithKline Newsroom
Analysts Offer Insights on Healthcare Companies: GlaxoSmithKline (GB:GSK), Sonova Holding AG (Six Swiss: CH:SOON) and Corbus Pharmaceuticals (CRBP)
Biogen (BIIB.US) and UCB's lupus new drug, daclizumab, late-stage trial successful, reversing early failures.
On Tuesday, BaiHealth and its Belgian partner UCB announced that the experimental lupus treatment drug Darzalex achieved the main goal in late-stage trials.
GSK's Menveo Meningococcal Vaccine in New Single-vial, Fully Liquid Presentation Receives Positive European CHMP Opinion
Sword of Justice! The US FTC sues three major pharmaceutical "middlemen", vows to correct the distorted profit chain.
The USA's FTC announced on its official website that it has filed a lawsuit against three major "pharmacy benefit managers" and their affiliated organizations, accusing them of engaging in anti-competitive and unfair kickback practices. FTC also "clearly stated" in the declaration its deep concern about the roles played by eli lilly and co, novo-nordisk a/s, sanofi, and other insulin pharmaceutical companies, and the competition bureau may recommend prosecuting these pharmaceutical companies in future enforcement actions.
GlaxoSmithKline Sell Rating Justified by Earnings Concerns and Market Challenges
Alector Presents Baseline Data For INFRONT-3 Phase 3 Trial Of Latozinemab At ISFTD 2024, Targeting Frontotemporal Dementia With Progranulin Gene Mutation (FTD-GRN)
US stock market closing: The roller coaster trend of the interest rate night is alarming, and the three major indexes closed slightly lower.
① Most China concept stocks in hot demand fell, with the Nasdaq China Golden Dragon Index dropping 0.86%; ② Space concept stock Intuitive Machines surged 38%; ③ The Federal Reserve cut interest rates dramatically by 50 basis points, but Powell claimed not to be eager to ease policy; ④ Boeing will implement unpaid leave measures in the coming days.
AstraZeneca Fasenra Gains Additional Indication
AstraZeneca's Asthma Drug Gets FDA Approval For Rare Disease Of Blood Vessel Inflammation
GlaxoSmithKline has reached settlements regarding two lawsuits in California related to the heartburn medication Zantac.
On September 18, GlaxoSmithKline, a pharmaceutical company in the united kingdom, announced that it has agreed to settle two lawsuits filed in California alleging that its discontinued heartburn drug Zantac could cause cancer. GlaxoSmithKline stated in a statement that the company does not admit any responsibility in these two settlements. Over the past 12 months, GlaxoSmithKline has resolved a series of lawsuits related to Zantac, including several in California.
GSK Settles Two California Lawsuits Related to Zantac
Roivant Flips a Skin Drug to Organon -- Barrons.com
GSK's Respiratory Syncytial Virus Vaccine Given Together With Shingles Shot Shows Non-Inferior Immune Response In Older Adults
Jefferies Sticks to Their Buy Rating for GlaxoSmithKline (GSK)
GSK Does Not Admit Any Liability in Either Settlement
GSK: Cases Will Now Be Dismissed as to GSK
GSK: Settlements Relate to Zantax Litigation
GSK Reaches Two Confidential Settlements in Cases Filed in California State Court
GSK Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX
Statement: Zantac (Ranitidine) Litigation – Russell and Hughes Cases